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Background: Depressive Disorders (DD) are a great financial and social burden. Females display 70% higher rate of
depression than males and more than 30% of these patients do not respond to conventional medications. Thus
medication-refractory female patients are a large, under-served, group where new biological targets for intervention
are greatly needed.
Methods: We used real-time quantitative polymerase chain reaction (qPCR) to evaluate mRNA gene expression
from peripheral blood leukocytes for 27 genes, including immune, HPA-axis, ion channels, and growth and
transcription factors. Our sample included 23 females with medication refractory DD: 13 with major depressive
disorder (MDD), 10 with bipolar disorder (BPD). Our comparison group was 19 healthy, non-depressed female
controls. We examined differences in mRNA expression in DD vs. controls, in MDD vs. BPD, and in patients with
greater vs. lesser depression severity.
Results: DD patients showed increased expression for IL-10, IL-6, OXTR, P2RX7, P2RY1, and TRPV1. BPD patients
showed increased APP, CREB1, NFKB1, NR3C1, and SPARC and decreased TNF expression. Depression severity was
related to increased IL-10, P2RY1, P2RX1, and TRPV4 expression.
Conclusions: These results support prior findings of dysregulation in immune genes, and provide preliminary
evidence of dysregulation in purinergic and other ion channels in females with medication-refractory depression,
and in transcription and growth factors in those with BPD. If replicated in future research examining protein levels
as well as mRNA, these pathways could potentially be used to explore biological mechanisms of depression and to
develop new drug targets.
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For the many millions of patients who suffer from clinical
depression worldwide, currently available antidepressant
medications are effective in inducing sustained remission in
less than half [1,2]. Patients who do not demonstrate symp-
tom remission after two trials with antidepressants from
different pharmacological classes are termed medication-* Correspondence: eli.iacob@gmail.com
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reproduction in any medium, provided the orresistant or medication-refractory. For these nonresponders
to standard antidepressant treatments, there is urgent
need to identify new potential targets for treatment, or
to re-examine targets that were previously studied only
in a heterogeneous pool of patients with depression.
One approach to examining multiple potential molecu-
lar targets efficiently is to use leukocyte gene expression
(mRNA) as biomarkers, which can be quantitatively
compared to healthy controls or to other patient groups
to indicate whether a specific target gene is over- or
under-expressed.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the course of depression and the response to antidepres-
sant treatment. Women have a higher lifetime prevalence
of depression than men [3] and the duration of treatment-
induced remission is shorter for women than men [2].
Also, human postmortem studies of regional brain mRNA
markers in depression have identified different patterns in
females vs. males [4,5]. Consequently, one strategy to re-
duce heterogeneity when studying depressed patients
employed by several recent studies is to focus exclusively
on females [6-8].
Although there are numerous studies that report on
gene expression differences in actively depressed patients
with major depressive disorder (MDD) or bipolar disorder
(BPD) compared to controls [9-11], few investigations
have focused specifically on MDD and BPD patients with
medication-refractory depression. Recently, Cattaneo et al.
examined gene expression for the glucocorticoid receptor
and related hypothalamic-pituitary-adrenal (HPA) axis
genes, for pro- and anti-inflammatory cytokines, and for
neuroplasticity and growth regulating factors in depressed
patients prior to treatment with escitalopram or nortripty-
line [12]. They reported that prior to starting treatment,
higher expression of three pro-inflammatory cytokines
was seen in those who subsequently were non-responders
to treatment: TNF (formerly known as TNFα), interleukin
(IL)-1β, and the macrophage inhibiting factor. Interest-
ingly, compared to healthy controls, both treatment re-
sponders and non-responders also had elevated levels of
these 3 cytokines and IL-6 but decreased levels of the
glucocorticoid receptor NR3C1 and of three genes re-
lated to neuroplasticity prior to treatment. There was
no treatment-related normalization for cytokines IL6
and TNF or for two of the neuroplasticity genes among
the medication-refractory depressed patients, while
medication-responsive patients did show normalization
in all of these except TNF.
In the present study, we compared expression of 27
target genes in women with medication-refractory de-
pression and healthy controls (see Table 1 for candidate
genes and functional classes). We included genes previ-
ously implicated in clinical depression as well as more
novel candidate genes previously studied in animal
models of depression and anxiety but not in MDD or
BPD patients. The target genes included 18 representing
the three categories examined by Cattaneo et al. [12].
For the glucocorticoid pathway, we included the gluco-
corticoid and mineralocorticoid receptors, NR3C1 and
NR3C2, respectively. Also related to the glucocorticoid
pathway were the oxytocin prepropeptide and oxytocin
receptor, OXT and OXTR, respectively. Oxytocin recep-
tor polymorphisms have been associated with depression
and anxiety [13-15], and oxytocinergic activity has been
shown to be dysregulated in women with both unipolarand bipolar depression [16-18], and it has been suggested
as a potential therapeutic target for mental disorders
[19,20]. For cytokines, we included pro-inflammatory
TNF, LTA, and IL-6, as well as anti-inflammatory IL-10.
For neuroplasticity and growth regulation, we included 10
genes: APP, CREB1, DBI, NFKB1, NRG1, PPARA, SIRT1,
SPARC, STAT5A, and VEGFA. We also included another
category of target mRNAs that have not yet been exam-
ined on leukocytes of patients with refractory depression
but have been reported to be dysregulated in patients with
Chronic Fatigue Syndrome (CFS) and Fibromylagia (FM),
many of whom had depressive symptoms [21] and are
implicated in animal models of anxiety and depression
[22-24]. These are ion channel receptors responding to
ATP or ADP and other metabolites, and included acid
sensing ion channels ASIC1 and ASIC3, and purinergic
receptors P2RX1, P2RX4, P2RX7, P2RY1 and P2RY2. Also
included were two transient vanilloid receptors, TRPV1
(the capsaicin receptor) and TRPV4 (another heat recep-
tor). Smolin et al. previously reported that ASIC1 expres-
sion was dysregulated in postmortem brain tissue of
patients with psychiatric disorders [25]. Perreira et al. have
recently reported that non-selective P2 receptor antago-
nists, more specifically P2X antagonists, have antidepres-
sant effects in mice [26]. Several studies have also
identified single nucleotide polymorphisms (SNPs) of the
P2RX7 receptor to be significantly associated with both
MDD and BPD [27], and this purinergic receptor was
under-expressed in patients with post-traumatic stress dis-
order, including many with comorbid depression [28]. Our
goals were: 1) to extend prior findings indicating that
neuroplasticity, cytokine, and glucocorticoid mRNAs
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ity) were differentially expressed on leukocytes in women
with medication-refractory depression vs. controls, and in
patients with BPD vs. MDD; 2) to provide an initial exam-
ination of possible differential leukocyte expression of ion
channel receptors in these same patient groups, and 3) to
identify any of these mRNAs that were correlated with de-
pression symptom severity, defined by self-report scores




All participants were non-pregnant and 20–72 years old.
All subjects gave written consent, and protocols were
reviewed and approved by the Institutional Review Board
at the University of Utah. The Depression Disorders (DD)
group included 23 females in an active state of moderate to
severe depression who were receiving a consult for Electro-
convulsive Therapy (ECT) having had unsatisfactory
response to three or more different antidepressant medica-
tion regimens. Diagnosis of MDD (n=13, ages 26–60) or
BPD (n=10, ages 26–72) was made by psychiatrists HW
and LB according to the criteria in the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV) [29]. Diagnosis, current medications, inpatient/
outpatient status, and medical comorbidities for each indi-
vidual patient, are included as Additional file 1: Table S1.
Clinical assessment of depression severity (Table 2)
was carried out using the Hamilton Rating Scale of De-
pression (HRSD)-24 score, a structured clinical inter-
view, scored by the psychiatrist and other trained staff
during the initial clinical visit prior to any change in
treatment [30,31]. Depression severity was also assessed
using the Quick Inventory of Depressive Symptomatol-
ogy (QIDS) Self Report either at the initial visit or an-









Age (years) 46.6±2.9 44.6±3.3 48.1±4.6 46.1±2.7
HRSD 36.6±3.7 33.8±3.0 35.4±2.4
QIDSA 3.32±0.6 19.67±1.5 19.38±1.3 19.55±1.0
No medication 17 0 0 0
AntidepressantsB 0 13 6 19
Anticonvulsants
(N/S/C)C
(17/0/2) (3/2/8) (3/1/6) (6/3/14)
Antipsychotic 0 5 6 11
AQIDS was significantly higher in MDD (p <0.001), BPD (p <0.001), and DD
(p <0.001) relative to CON.
BAntidepressant use has higher in MDD vs. BPD χ2 4.749 (p =0.01) and vs. CON
(p <0.01).
CAnticonvulsant (N = not on, S = stopped in anticipation of ECT,
C = currently on).The QIDS self report has been found to have concurrent
validity with the clinician based QIDS and the Hamilton
Rating Scale of Depression [32]. The control group
(CON), which included 19 individuals, 23–68 years old,
also completed the QIDS, and provided demographic and
medical history information including history of depres-
sion and other mental disorders. We excluded any con-
trols that had been previously diagnosed with depression,
were currently taking antidepressants, or had a QIDS
score in the mild or greater depression range. Evaluation
of medication-responsive subjects is left for a future study.
Concurrent with behavioral assessment, blood samples
were obtained from each participant based on patient
and psychiatrist availability between 10 am-3 pm. Patients
and controls were matched for age, with no significant dif-
ferences between groups (t = 0.1135, p = 0.91). Anti-
depressant use was significantly higher in patients with
MDD vs. BPD (χ2 = 6.29, p = 0.03). There were no dif-
ferences between MDD and BPD for anticonvulsant
use (χ2 = 0.232, p = 0.891) or antipsychotics (χ2 = 0.306,
p = 0.580).
mRNA extraction and analysis
All blood processing was performed by personnel blinded
to the subjects’ group. Blood was collected in EDTA tubes
and kept on ice. Within 15 minutes after collection, the
blood was centrifuged at 3200 rpm (1315 × g- Clay Adams
Compact II Centrifuge) for 12 minutes, plasma was re-
moved, and the white layer was carefully collected in
RLT+β-ME (Qiagen, Valencia, CA), then quickly frozen
using a methanol-dry ice slurry, and stored at −80°C.
RNA was extracted using RNeasy mini kits (Qiagen,
Valencia, CA), and treated with RNase-free DNase-I
(Qiagen, Valencia, CA). Immediately following extrac-
tion, RNA was converted to a cDNA library using the
ABI High Capacity cDNA Archive Kit (Applied
Biosystems/Life Technologies, Inc., Foster City, CA),
followed by treatment with RNase-H (Epicentre Bio-
technologies, Madison, WI). The cDNA samples were
stored at -20°C until further use. RNA integrity was
assessed with a Bioanalyzer, and consistently found to
have RIN values (RNA integrity numbers) greater than
9. The cycle counts for the control gene, TF2B, averaged
22.81 ± 0.16 (SE) for DD patients and 23.21 ± 0.19 for
CON subjects (t = 1.63, p = 0.11). We selected TF2B as
the preferred control gene and have verified that TF2B
qPCR counts do not change in freshly harvested sepa-
rated human leukocytes under a variety of conditions,
when RNA is processed as described here.
The cDNA libraries were analyzed using the ABI
quantitative, real-time PCR system on the ABI Prism
7900 Sequence Detection System (SDS) 2.4.1 (Applied
Biosystems, Inc., Foster City, CA), using ABI TaqMan
Master Mix (Applied Biosystems, Inc., Foster City, CA).
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template solutions were separately loaded onto 96 well
source plates. Then 384 well plates were robotically
loaded and mixed from the 96 well plates. Each targeted
gene was examined in duplicate, with TF2B standards
being run in quadruplicate. Additional control samples
containing no template were also run. Primer-probes
for the 27 candidate genes were obtained from TaqMan
Gene Expression Assays (Applied Biosystems, Inc.,
Foster City, CA) and are listed in Additional file 2:
Table S2. qPCR data was processed using the SDS pro-
gram, with count values for genes computed in the
curve log-linear range using a standard 0.2 threshold.
Gene expression amounts were determined using the
2-ΔT method, where ΔT is the count difference of the
candidate gene from TF2B.Statistical analysis
All statistical tests were made using STATA ver. 12
statistical software. Distributions of the mRNA data
showed considerable skew. To address this normality,
we performed all parametric tests using log transformed
data. To ensure that our data were not biased by out-
liers, we also repeated all tests with non-parametric
Wilcoxon rank-sum tests. First, we used General Linear
Models (GLM) to identify any differences in gene ex-
pression between all DD patients vs. nondepressed
CON; age was found to be a significant covariate for
only 2 genes, ASIC1 and LTA (p < 0.025), and so was
retained in those final models but dropped for the other
28 genes. Antidepressant and antipsychotic medication
use could not be included as a potential covariate in
these analyses because none of the healthy controls
were taking these medications. Cohen’s d effect sizes
were calculated for all between group comparisons.Table 3 Gene expression (mean ± SE) for genes differing betw
Controls (CON)
GENE CON (n=19) DD (n=23)
APP 5.65E-01 ± 3.12E-02 6.70E-01 ± 3.59E-02
IL-10 3.86E-03 ± 3.66E-04 5.27E-03 ± 5.33E-04
IL-6 2.02E-03 ± 2.79E-04 2.94E-03 ± 3.45E-04
OXTR 2.94E-03 ± 3.00E-04 4.75E-03 ± 6.95E-04
P2RX7 4.64E-02 ± 3.22E-03 5.84E-02 ± 4.89E-03
P2RY1 7.48E-02 ± 3.89E-03 9.45E-02 ± 5.82E-03
TRPV1 1.15E-02 ± 6.36E-04 1.35E-02 ± 5.07E-04
Raw data is displayed in the table. Expressed in scientific notation units where E+00
to analysis.
ADifferences between DD vs. CON examined using log transformed data and Stude
BDifferences between DD vs. CON examined using non-transformed data and nonp
All comparisons had 40 degrees of freedom and F values ranging from 4.29 – 6.42.
CCohen d effect sizes were all moderate to large and are reported with DD as the rSecond, using the mRNA data from the DD patients
only, we used multiple regression analysis to examine the
orthogonal effects of 5 factors: 1) BPD vs. MDD diagnosis,
2) depression severity (defined first by QIDS score, and
then repeated using HRSD score), 3) use of antidepressant
and antipsychotic medications (coded as 0=none, 1=
SSRI/SNRI/NRI antidepressants only, 2=antipsychotic
only, 3=antidepressants + antipsychotic), 4) use of anti-
convulsant (0=none or stopped, 1=anticonvulsant), and
5) age. In this second set of analyses, we thus could de-
termine whether there were differences in gene expres-
sion between BPD and MDD patients after controlling
for effects of depression severity and vice versa. We
also could assess whether either the diagnosis or sever-
ity factors remained significant after controlling for
medications and age. Alpha level for all analyses was
set at p < 0.05. η2 effect sizes were computed for re-
gression models.
Results
Differentially expressed genes in DD compared to CON
Our 27 candidate gene panel included genes from diverse
functional classes; however, only genes from the immune,
neuronal health and ion channel classes differed between
actively depressed patients and controls. We observed that
6 genes were significantly increased in DD relative to
CON [APP (F 1,40 =4.37, p = 0.043, Wilcoxon rank sum
on non-transformed data p = 0.029), IL-10 (F 1,40 =4.29,
p = 0.045, p = 0.039), IL-6 (F 1,40 = 5.18, p = 0.028,
p = 0.045), OXTR (F 1,40 = 5.27, p = 0.023, p = 0.037),
P2RX7 (F 1,40 = 4.40, p = 0.042, p = 0.050), P2RY1
(F 1,40 = 6.42, p = 0.015, p = 0.015), and TRPV1 (F 1,40 =
6.03, p = 0.019, p = 0.010)] (see Table 3). Age was not a
significant or marginally significant covariate for any of
these genes. None of our 27 candidate genes showed
significantly lower expression in DD versus CON.een all patients with Depressive Disorders (DD) versus
p valueA p valueB Cohen’s dC








= x1, E-01 = x0.1, E-02 = x0.01, etc. Data were log transformed prior
nt’s t-test.
arametric Wilcoxon Rank Sum test.
eference group.
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patient sample
In our 5-factor regression model, use of antidepressant
and antipsychotic medication was significantly related to
higher expression of NR3C2 (adjusted t = 2.60, p = 0.026)
and ASIC1 (adjusted t = 2.39, p = 0.029). However, this
medication factor was also marginally related to increased
or decreased expression of 3 other genes: OXTR (adjusted
t = −1.91, p = 0.073), SIRT1 (adjusted t = 1.77, p = 0.094),
ASIC3 (adjusted t = 2.01, p = 0.06). Given our relatively
small sample size, which limits statistical power, these
trends suggest that controlling for use of these medica-
tions is potentially important.
Anticonvulsant use was likewise marginally related
to increased VEGF (adjusted t = 1.88, p = 0.078), APP
(adjusted t = 2.01, p = 0.061), and ASIC3 (adjusted t =
1.96, p = 0.067). Thus, we felt that it was important to
retain both medication factors in our final models, and
thus to examine effects of other factors after adjust-
ment for use of these different types of medications.
Age was significantly related to lower expression of 2
genes, NFKB1 (adjusted t = −2.98, p = 0.008) and LTA
(adjusted t = −3.11, p = 0.006).Effects of BPD versus MDD diagnosis
After controlling for medications, age and depression
severity, currently depressed patients with a diagnosis of
BPD showed higher expression of 5 genes and lower ex-
pression of 1 gene than patients with a diagnosis of MDD
(see Table 4). These over-expressed genes included 3 tran-
scription factors: CREB1 (adjusted t = −2.50, p = 0.023),
NFKB1 (adjusted t = −2.30, p = 0.035), and NR3C1 (ad-
justed t = −2.18, p = 0.044. They also included 2 matrix-
associated genes, APP (adjusted t = −3.13, p = 0.006) and
SPARC (adjusted t = −3.37, p = 0.004). Patients with BPD
displayed decreased expression in one immune gene, TNF
(adjusted t = 2.32, p = 0.033).Table 4 Gene expression (mean ± SE) for genes differing betw
GENE BPD (n=10) M
APP 7.63E-01± 4.80E-02 5.98E
CREB1 7.40E-01 ± 4.75E-02 6.39E
NFKB1 5.81E-01 ± 2.42E-02 5.29E
NR3C1 3.27E-01 ± 2.81E-02 2.78E
SPARC 3.20E+00 ± 2.72E-01 2.29E
TNF 1.36E-01 ± 5.99E-03 1.68E
Raw data is displayed in the table. Expressed in scientific notation units where E+00
to analysis.
ABPD vs. MDD using 5 factor regression model with inclusion of age, QIDS-SR, antic
5 variables, results in 17 degrees of freedom.
p value is for effect of Diagnostic subgroup after adjusting for the effects of the oth
Effect sizes using η2 for where diagnostic subgroup was significant in the regressioEffects of depression severity
After controlling for other factors listed above, depres-
sion severity (defined by QIDS score) was significantly
related to expression of 4 genes (Table 5). These in-
cluded increased expression of 3 ion channel genes:
P2RY1 (adjusted t = 3.12, p = 0.006), P2RX1 (adjusted t =
2.86, p = 0.011) and TRPV4 (adjusted t = 2.29, p = 0.035).
Severity was also associated with increased expression of
IL-10 (adjusted t = 2.28, p = 0.036). When other non-
significant components of the models were dropped, all of
these effects of depression severity on these 4 mRNAs
were significant (p<0.03). In a separate 5-factor regression
model using the clinical HRSD for depression severity,
severity was associated with increased expression of
P2RX1 (adjusted t = 2.44, p = 0.026) and P2RY1 (adjusted
t = 2.10, p = 0.051), but not TRPV4 (adjusted t = −0.14,
p = 0.893) or IL10 (adjusted t = −0.35, p = 0.734).
Discussion
New biological targets for treatment are urgently needed
for patients with depressive disorders (both unipolar and
bipolar), and the population where this need is most
critical are those with medication-refractory depression.
Identifying more of the diverse neuroimmune pathways
that may be dysregulated in these disorders provides a
first step in this process. As a screen for possible
dysregulation, we looked for increased or decreased gene
expression using qPCR from peripheral leukocytes in pa-
tients with medication-refractory depression vs. healthy
controls with no history of depression. Specifically, we
examined genes representing several biological pathways
including glucocorticoid receptors, immune function,
growth and transcription factors, and purinergic, transi-
ent vanilloid and acid sensing ion channel receptors. We
restricted our sample to females to eliminate gender as a
potential source of heterogeneity; however, we included
depressed patients with both MDD and BPD diagnoses
and secondarily examined differences in gene expressioneen BPD and MDD subgroups
DD (n=13) p valueA η2
-01 ± 4.33E-02 0.006 0.303
-01 ± 2.15E-02 0.028 0.210
-01 ± 1.99E-02 0.038 0.179
-01 ± 9.51E-03 0.043 0.191
+00 ± 1.80E-01 0.003 0.300
-01 ± 1.14E-02 0.032 0.200
= x1, E-01 = x0.1, E-02 = x0.01, etc. Data were log transformed prior
onvulsant use, and antidepressant/antipsychotic use. Model has 23 patients,
er 4 factors.
n model were consistently large (>0.14).
Table 5 Significant associations of depression severity
and gene expression for HRSD and QIDS controlling for
BPD vs. MDD diagnosis, age, and medication use
GENE QIDS t p value η2 HRSD t p value η2
P2RX1 2.86 0.011 0.296 2.44 0.026 0.236
P2RY1 3.12 0.006 0.333 2.10 0.051 0.189
TRPV4 2.29 0.035 0.234 −0.14 0.893 0.001
IL10 2.28 0.036 0.227 −0.35 0.734 0.007
Depression severity assessed by QIDS or HRSD using 5 factor regression model
with inclusion of diagnosis, age, anticonvulsant use, and antidepressant/
antipsychotic use. Model has 23 patients, 5 variables, results in 17 degrees
of freedom.
p value is for effect of depression severity after adjusting for the effects of the
other 4 factors.
Effect sizes using η2 for where depression severity was significant in the
regression model were large (>0.14) for the 4 genes using QIDS and for P2RX1
and P2RY1 using HRSD.
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medication use and depression severity. Finally, we exam-
ined relationships of increased or decreased expression to
greater symptom severity, after controlling for several
potential confounding factors, including medications.
Using this approach, our observations reconfirmed
dysregulation in two immune genes previously implicated
in depression: the cytokines IL-10 and IL-6 [33-35]. Our
findings also provided initial evidence of possible
dysregulation in 3 relatively novel targets for depression:
ion channels TRPV1, P2RX7 and P2RY1. All of the above
genes showed increased expression in DD patients com-
pared to healthy controls; none of our targeted genes
showed decreased expression among patients. With the
DD sample, greater depression severity (whether defined
by QIDS or by HRSD scores) was associated with higher
expression of ion channels P2RX1 and P2RY1. In addition,
greater depression was associated with higher expression
of IL-10 and TRPV4 using QIDS as the severity measure.
These associations further strengthen the interpretation
that IL-10 and ion channels are prominent targets
for intervention development in medication-refractory
depression.
Further analyses suggested possible differences be-
tween BPD and MDD subgroups after controlling the
effects of medication use and depression severity.
These genes included 2 genes in the HPA-immune
axis: the glucocorticoid receptor NR3C1 and the cyto-
kine TNF which were upregulated and downregulated
in BPD, respectively. They also included upregulation
of 2 transcription factors with widespread effects on
regulation of other neuroimmune genes: CREB1 and
NFKB1. In addition, they included upregulation of 2
matrix-associated growth factors, SPARC and APP.
Although APP was also seen to be up-regulated in all
DD patients versus healthy controls, examination of
the group means (Tables 3 and 4) showed that this
effect was primarily due to the BPD group.Differentially expressed genes and their possible
functional significance
Gene expression dysregulation may be indicative of imbal-
ance or dysfunction in these biological pathways and
therefore, implicate potential drug targets. Clinical studies
previously have examined the effects of antidepressant
and antipsychotic medications on biomarkers of inflam-
mation [36-38], glucocorticoid receptors [39], glutamate
[40], and neuropeptides [19], among others. Immune and
HPA axis activity have thus been the most common tar-
gets of antidepressant intervention [41-43] other than
monoamine systems involving serotonin and norepineph-
rine which are primary targets of SSRI/SNRI/NRI and
tricylic medications.
Consistent with previous studies on mRNA in blood
of patients with depression, both medication responders
and non-responders, we found upregulation in cytokines
IL-6 and IL-10 in females with medication-refractory
depression [9,12,44]. Protein elevations of both cytokines
in serum and CSF are a consistent finding in depression
[41,45,46], with some studies suggesting that IL-6 is spe-
cifically associated with medication-refractory depres-
sion, and that IL-10 levels decrease following successful
treatments [33-35]. Because we found that IL-10 levels
were positively correlated with depression severity, it will
be important for future studies to examine gene expres-
sion levels following symptom remission.
Our finding of increased peripheral OXTR mRNA in
DD patients may reflect dysregulation in oxytocinergic sig-
naling. Also, the trend shown in the present study for the
association between the use of antidepressant medications
and lower OXTR expression suggests that such decreases
may contribute to beneficial effects of these medications.
Oxytocin is a neuropeptide that is synthesized and
released by the hypothalamus, and has been implicated in
many biological functions, including social bonding, anx-
iety, pleasure-seeking, appetite, and stress response, all of
which can be disrupted in depression [47]. Most studies
suggest that low plasma and CSF levels of oxytocin are
associated with depressive behaviors and increased sensi-
tivity to stressors, and that such differences may be spe-
cific to depressed females rather than to males [18,47,48].
Furthermore, subjects with depression display greater
fluctuations in oxytocin in response to stressful mental
tasks, suggesting dysregulation [16,49]. In addition,
polymorphisms in the OXTR can result in decreased
receptor expression, symptoms of depression and anx-
iety, and sensitivity to stressors [13-15]. Since intrana-
sal oxytocin may have beneficial effects on depressive
symptoms and anxiety, patients displaying oxytocin
pathway mRNA dysregulation could benefit from such
a targeted treatment [17].
Of the growth factors that we examined, we observed
that female patients with depression displayed elevated
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pared to healthy non-depressed controls. Subsequent
analysis found that patients with BPD had higher levels
of APP compared to MDD suggesting increases vs. CON
are primarily due to the BPD subgroup. APP (most not-
able for its association with Alzheimer's Disease) plays
multiple roles, for instance that of a neuronal growth
factor and in transcriptional regulation, with compli-
cated post-translational processing resulting in multiple
cleaved peptides. Therefore, the increased APP gene
expression that we observed may be due to compensation
for low peripheral levels of peptides, or to non-functional
peptides. For example, alterations in CSF APP peptides
have been observed in patients with BPD, including de-
creased levels of sAPP-α and sAPP-β in Bipolar type I and
changes in ratios for other Aβ peptide products in Bipolar
type II [50]. Decreased levels of Aβ40 and Aβ42 have also
been observed in the CSF and serum of depressed patients
with levels correlating to depression severity [51-53],
though both increased and decreased levels of Aβ42 have
been found in human plasma [54,55]. Given the complex
post-transcriptional processing of APP, future studies
should combine mRNA and protein analysis to determine
the relationship between APP transcript levels and peptide
products, and if levels differ between medication-
refractory and medication-responsive patients.
Our gene expression panel also consisted of several
ligand-gated channel families important in detecting
ATP and other metabolites that may be related to pain
and fatigue, frequent symptoms in DD. Of the 9 ion
channel receptors that we examined, P2RX7, TRPV1,
and P2RY1 were upregulated in female patients during a
depressive episode, and P2RY1 expression was positively
related to depression severity along with 2 other ion
channel receptors, TRPV4 and P2RX1. Our clinical find-
ings in regard to P2RY1, P2RX1, TRPV1, and TRPV4
mRNAs are the first such observations in depressed
humans; however they are consistent with a number of
preclinical and genetic studies. Modulation of TRPV1 and
P2RY1 receptors in animals has effects on depression and
anxiety tasks [23,24,56]. Furthermore, our research group
previously found that following a moderate exercise task,
when their fatigue and pain symptoms worsen, patients
with CFS show increased expression of ion channels, with
expression levels positively correlated with pain and
fatigue symptoms [21,57]. While the role of peripheral
P2RY1 receptor function in human depression is un-
known, it is promising that we observed gene expression
increases in DD that were also positively correlated to de-
pression severity, suggesting either that increased expres-
sion may be involved in symptom presentation or that it is
compensatory for receptor dysfunction.
Some prior studies have suggested that certain polymor-
phisms in P2RX7 may predispose individuals to MDD,although these findings have been disputed by others
[58-60]. Our results of increased P2RX7 mRNA expres-
sion in patients with medication refractory DD are con-
trary to those reported by Zhang et al., who found
decreased peripheral expression of P2RX7 in psychiatric
patients (primarily female) with post-traumatic stress dis-
order or MDD, and similar mRNA decreases in postmor-
tem tissue from suicide victims in a meta analysis [28].
Our samples are clearly different in several characteristics,
but it is also possible that our increased peripheral recep-
tor mRNA reflects secondary compensatory increases to
diminished central activity in this pathway. Still, our obser-
vations as those of Zhang et al. are consistent in indicating
dysregulation in this purinergic pathway in DD.
Although purinergic P2X and P2Y, acid-sensing ASIC,
and transient vanilloid TRPV ion channels have been
the target for the treatment of multiple other disorders,
including thrombosis, cardiac arrhythmias, and neuro-
pathic pain [61,62], these pathways have not yet been ex-
amined for antidepressant effects in patients with MDD
or BPD. Given the numerous animal studies implicating
ion channels including P2X, P2Y, and TRPV receptor
function in anxiety- and depression-like states, and our
studies showing dysregulation in these ion channel recep-
tors in refractory depression, further investigation of drugs
or other interventions targeting ion channels for depres-
sive symptoms may be warranted.
Though still in their infancy, gene expression studies
may one day help to identify individuals that would most
benefit from drugs targeting non-monoamine pathways.
Effects of medications, clinical diagnosis, and depression
severity on gene expression
In order to explore possible confounders in our DD
sample, we included medication use, depression sever-
ity, and DD diagnosis in a five-factor regression model.
Medications have been shown to affect immune func-
tion and alter gene expression [10,37,63-66]. We found
significant effects of medication for NR3C2, ASIC1, and
APP with ASIC3, OXTR, and SIRT1 showing marginal
effects. Importantly, with the exception of APP and
OXTR, none of these genes were identified in either our
DD vs. CON or BPD vs. MDD analyses. Decreased ex-
pression of OXTR with medication use suggests that
medications may have minimized rather than contributed
to the higher expression in DD vs. CON. Conversely, anti-
convulsant use was associated with higher expression of
APP and therefore medication use could have contributed
to elevated levels in DD vs. CON. Future work should
continue to consider the effects of medication use on gene
expression and how it may accentuate or mask group
differences.
In our sample we focused on patients that were cur-
rently in a depressive state. This included patients with
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showed group differences after controlling for concurrent
psychotropic medication use, age, and depression severity.
These included BPD elevations in transcription factors
CREB1, NR3C1, and NFKB1, matrix-associated genes
APP and SPARC, and downregulation of proinflammatory
cytokine TNF. Of these genes, only APP was also found to
be confounded by anticonvulsant use. However, robust
differences persisted even after controlling for medication
use. The same genes displayed differences between BPD
and MDD when using HRSD. These are promising
results that suggest possible biomarker differences be-
tween these diagnostic groups, but future replication
studies are necessary.
Finally, we examined associations between depression
severity and gene expression using both the clinical
interview HRSD and QIDS self report scores. Both the
QIDS and HRSD displayed positive associations for de-
pression and gene expression for ion channels P2RX1
and P2RY1, further strengthening the possible relation-
ship of ion channels and depression. In addition, QIDS
had a positive association for another ion channel,
TRPV4, and for the cytokine IL10, which was also iden-
tified as up-regulated in DD vs. CON in the primary
analysis. HRSD score was not associated with these latter
two genes (Table 5). Although QIDS and HRSD scores
were strongly related to each other (R2 = 0.586, p = 0.003),
as is always true, they were not identical. Future
mRNA studies may benefit by including both assess-
ment methods.
Limitations
There are several noteworthy limitations to this study.
Because we examined female subjects only, it is not pos-
sible to conclude whether the observed gene expression
differences would extend to depressed males or repre-
sent true gender-specific differences. Secondly, in this
study we did not include control subjects taking antide-
pressants or antipsychotics. For example, since there
were only 4 DD patients that were not taking antide-
pressants, it is possible that gene expression differences
were influenced by antidepressant use. Medication-
responsive control subjects likely represent a distinct
group from healthy non-depressed controls and must be
treated differently. In our regression analysis of de-
pressed patients only, we did find that medication use
led to differences in expression when controlling for age,
depression severity, and diagnosis, including increased
expression of ASIC receptors, transcription factor
NR3C2, and growth factor APP. It is critical for future
studies to examine gene expression in light of medication
use. Thirdly, our primary analysis combined patients with
BPD and MDD into a single group when comparing to
non-depressed controls. This was done partially becauseall of our patients were currently in a depressed state. Fur-
ther regression analysis controlling for depression severity,
age, and medication, revealed several potential differences
based on diagnosis. These results are promising in the
search for potential diagnostic biomarkers, but our small
sample size warrant future studies where BPD and MDD
groups with adequate power are also examined separately
compared to controls. Finally, it is important to note
that depression remains enigmatic and difficult to treat,
partially because of the diversity of disease onset, symp-
tom presentation, comorbidities, and disease evolution.
Current studies are under way in patients with depres-
sion to examine gene expression changes following
moderate exercise tasks, found to differentiate patients
with CFS and FM from controls. Similar to the study by
Cattaneo et al. [12], future research should compare
gene expression over time for treatment-resistant and
treatment-responsive patients in prospective studies
before and after symptom remission. By amassing a
panel of differentially expressed genes, researchers
could continue to identify novel biological mechanisms
contributing to depression and potentially pave the way
to new drug targets and personalized medicine.
Conclusions
The principal finding of this study is that women with
medication-refractory depression display increased expres-
sion of genes from diverse biological pathways, including
the immune genes IL10 and IL6, the oxytocin receptor
OXTR, the growth factor APP, and the metabolite recep-
tors P2RY1, P2RX7, and TRPV1. Furthermore, differences
between MDD and BPD were seen for matrix-associated
growth factors APP and SPARC, immune gene TNF, and
transcription factors CREB1, NFKB1, and NR3C1 when
controlling for depression severity, age, and medication
use. Finally, two additional ion channel genes, P2RX1 and
TRPV4, as well as two of the genes from our primary ana-
lysis, IL-10 and P2RY1, were related to depression severity
as assessed by the QIDS and/or HRSD. Future replication
studies, particularly those measuring protein levels as
well as mRNA, are still needed to strengthen the case
for development of new targeted treatments.
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